Enanta Pharmaceuticals (ENTA) Revenue Growth (5y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.15% |
| Dec 31, 2025 | -10.12% |
| Sep 30, 2025 | -8.54% |
| Jun 30, 2025 | -0.37% |
| Mar 31, 2025 | -11.58% |
| Dec 31, 2024 | -20.25% |
| Sep 30, 2024 | -22.22% |
| Jun 30, 2024 | -16.54% |
| Mar 31, 2024 | -15.52% |
| Dec 31, 2023 | -23.76% |
| Sep 30, 2023 | -22.38% |
| Jun 30, 2023 | -19.89% |
| Mar 31, 2023 | -16.58% |
| Dec 31, 2022 | -9.15% |
| Sep 30, 2022 | -23.18% |
| Jun 30, 2022 | 21.00% |
| Mar 31, 2022 | 15.88% |
| Dec 31, 2021 | 21.56% |
| Sep 30, 2021 | 12.92% |
| Jun 30, 2021 | 9.12% |
| Mar 31, 2021 | 9.13% |
| Dec 31, 2020 | -8.11% |
| Sep 30, 2020 | 10.39% |
| Jun 30, 2020 | 9.97% |
| Mar 31, 2020 | -13.60% |
| Dec 31, 2019 | -7.47% |
| Sep 30, 2019 | 81.06% |
| Jun 30, 2019 | 1.08% |
| Mar 31, 2019 | 78.94% |
| Dec 31, 2018 | 139.17% |
| Sep 30, 2018 | 118.51% |
| Jun 30, 2018 | 103.30% |
| Mar 31, 2018 | 105.70% |
| Dec 31, 2017 | 6.47% |
| Sep 30, 2017 | 110.02% |
| Jun 30, 2017 | 24.20% |
| Mar 31, 2017 | -24.52% |